[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.167.142.229. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
December 23, 1992

FDA Committee Recommends Combined DTP, Haemophilus influenzae Vaccine

JAMA. 1992;268(24):3415. doi:10.1001/jama.1992.03490240015004

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.

Abstract

A SIMPLIFIED PEDIATRIC immunization schedule appears about ready to become a reality.

The Food and Drug Administration (FDA), Rockville, Md, has been advised by one of its review committees to license a combined diphtheria-tetanus-(whole-cell) pertussis vaccine linked with a Haemophilus influenzae type b conjugate vaccine. The result would be to reduce by half the number of injections that infants and children receive to be immunized against these diseases.

David McLintock, PhD, Lederle-Praxis Laboratories, a division of American Cyanamid Co, Wayne, NJ, says: "The two vaccines overlap in their use, being given at 2, 4, and 6 months of age with a booster at 15 to 18 months. So it was natural to combine them into a single ready-to-use vaccine."

Advisory Committee Meeting  McLintock spoke at a meeting of the advisory committee on vaccines and related biological products of the FDA's Center for Biologics and Evaluation and Research. Although there was

×